Small cell lung cancer

Have we made any progress over the last 25 years?

Brian E. Lally, James J. Urbanic, A. William Blackstock, Antonius A. Miller, Michael C. Perry

Research output: Contribution to journalArticle

135 Citations (Scopus)

Abstract

Twenty-five years ago, small cell lung cancer was widely considered to be the next cancer added to the list of "curable cancers." This article attempts to summarize the progress made toward that goal since then. Clinical trials have provided landmarks in the therapy of limited-stage small cell lung cancer (LS-SCLC). These are: (a) the proof that thoracic radiation therapy adds to systemic chemotherapy, (b) the superiority of twice-daily radiation therapy over daily fractionation, and (c) the need for prophylactic central nervous system radiation (prophylactic cranial irradiation). Each of these innovations adds about 5%-10% to the overall survival rate. In extensive-stage disease, irinotecan plus cisplatin may be a possible alternative to the "standard" etoposide-cisplatin chemotherapy doublet, but there has been little progress otherwise. It is imperative that, whenever possible, patients be given the opportunity to participate in future clinical trials so that the survival for these patients can continue to improve.

Original languageEnglish
Pages (from-to)1096-1104
Number of pages9
JournalOncologist
Volume12
Issue number9
DOIs
StatePublished - Sep 1 2007

Fingerprint

irinotecan
Small Cell Lung Carcinoma
Cisplatin
Radiotherapy
Clinical Trials
Cranial Irradiation
Drug Therapy
Etoposide
Neoplasms
Thorax
Survival Rate
Central Nervous System
Radiation
Survival
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

Lally, B. E., Urbanic, J. J., Blackstock, A. W., Miller, A. A., & Perry, M. C. (2007). Small cell lung cancer: Have we made any progress over the last 25 years? Oncologist, 12(9), 1096-1104. https://doi.org/10.1634/theoncologist.12-9-1096

Small cell lung cancer : Have we made any progress over the last 25 years? / Lally, Brian E.; Urbanic, James J.; Blackstock, A. William; Miller, Antonius A.; Perry, Michael C.

In: Oncologist, Vol. 12, No. 9, 01.09.2007, p. 1096-1104.

Research output: Contribution to journalArticle

Lally, BE, Urbanic, JJ, Blackstock, AW, Miller, AA & Perry, MC 2007, 'Small cell lung cancer: Have we made any progress over the last 25 years?', Oncologist, vol. 12, no. 9, pp. 1096-1104. https://doi.org/10.1634/theoncologist.12-9-1096
Lally BE, Urbanic JJ, Blackstock AW, Miller AA, Perry MC. Small cell lung cancer: Have we made any progress over the last 25 years? Oncologist. 2007 Sep 1;12(9):1096-1104. https://doi.org/10.1634/theoncologist.12-9-1096
Lally, Brian E. ; Urbanic, James J. ; Blackstock, A. William ; Miller, Antonius A. ; Perry, Michael C. / Small cell lung cancer : Have we made any progress over the last 25 years?. In: Oncologist. 2007 ; Vol. 12, No. 9. pp. 1096-1104.
@article{749c409c693246ef917543d982a36047,
title = "Small cell lung cancer: Have we made any progress over the last 25 years?",
abstract = "Twenty-five years ago, small cell lung cancer was widely considered to be the next cancer added to the list of {"}curable cancers.{"} This article attempts to summarize the progress made toward that goal since then. Clinical trials have provided landmarks in the therapy of limited-stage small cell lung cancer (LS-SCLC). These are: (a) the proof that thoracic radiation therapy adds to systemic chemotherapy, (b) the superiority of twice-daily radiation therapy over daily fractionation, and (c) the need for prophylactic central nervous system radiation (prophylactic cranial irradiation). Each of these innovations adds about 5{\%}-10{\%} to the overall survival rate. In extensive-stage disease, irinotecan plus cisplatin may be a possible alternative to the {"}standard{"} etoposide-cisplatin chemotherapy doublet, but there has been little progress otherwise. It is imperative that, whenever possible, patients be given the opportunity to participate in future clinical trials so that the survival for these patients can continue to improve.",
author = "Lally, {Brian E.} and Urbanic, {James J.} and Blackstock, {A. William} and Miller, {Antonius A.} and Perry, {Michael C.}",
year = "2007",
month = "9",
day = "1",
doi = "10.1634/theoncologist.12-9-1096",
language = "English",
volume = "12",
pages = "1096--1104",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "9",

}

TY - JOUR

T1 - Small cell lung cancer

T2 - Have we made any progress over the last 25 years?

AU - Lally, Brian E.

AU - Urbanic, James J.

AU - Blackstock, A. William

AU - Miller, Antonius A.

AU - Perry, Michael C.

PY - 2007/9/1

Y1 - 2007/9/1

N2 - Twenty-five years ago, small cell lung cancer was widely considered to be the next cancer added to the list of "curable cancers." This article attempts to summarize the progress made toward that goal since then. Clinical trials have provided landmarks in the therapy of limited-stage small cell lung cancer (LS-SCLC). These are: (a) the proof that thoracic radiation therapy adds to systemic chemotherapy, (b) the superiority of twice-daily radiation therapy over daily fractionation, and (c) the need for prophylactic central nervous system radiation (prophylactic cranial irradiation). Each of these innovations adds about 5%-10% to the overall survival rate. In extensive-stage disease, irinotecan plus cisplatin may be a possible alternative to the "standard" etoposide-cisplatin chemotherapy doublet, but there has been little progress otherwise. It is imperative that, whenever possible, patients be given the opportunity to participate in future clinical trials so that the survival for these patients can continue to improve.

AB - Twenty-five years ago, small cell lung cancer was widely considered to be the next cancer added to the list of "curable cancers." This article attempts to summarize the progress made toward that goal since then. Clinical trials have provided landmarks in the therapy of limited-stage small cell lung cancer (LS-SCLC). These are: (a) the proof that thoracic radiation therapy adds to systemic chemotherapy, (b) the superiority of twice-daily radiation therapy over daily fractionation, and (c) the need for prophylactic central nervous system radiation (prophylactic cranial irradiation). Each of these innovations adds about 5%-10% to the overall survival rate. In extensive-stage disease, irinotecan plus cisplatin may be a possible alternative to the "standard" etoposide-cisplatin chemotherapy doublet, but there has been little progress otherwise. It is imperative that, whenever possible, patients be given the opportunity to participate in future clinical trials so that the survival for these patients can continue to improve.

UR - http://www.scopus.com/inward/record.url?scp=35548956927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35548956927&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.12-9-1096

DO - 10.1634/theoncologist.12-9-1096

M3 - Article

VL - 12

SP - 1096

EP - 1104

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 9

ER -